Hormonal
Intermittent fasting significantly reduces diastolic blood pressure but has no significant effect on systolic blood pressure, fasting plasma glucose, or HbA1c in overweight and obese adults.
Intermittent fasting can help lower diastolic blood pressure, a key component of heart health. However, it may not significantly affect systolic blood pressure or blood sugar levels (FPG, HbA1c) in the short term. For comprehensive cardiometabolic health, combine IF with other lifestyle interventions and monitor your specific markers.
In addition, IF significantly reduced DBP (MD: -3.30 mmHg, 95% CI: -5.47, -1.13) but had no significant effect on SBP, FPG and HbA1c.
Why this rating
Meta-analysis of RCTs, with clear subgroup findings for BP and glycemic markers.
Source
The impact of intermittent fasting on body composition and cardiometabolic outcomes in overweight and obese adults: a systematic review and meta-analysis of randomized controlled trials
Bingjie Wang et al. · Nutrition Journal · 2025
DOI 10.1186/s12937-025-01178-6
More from this paper
- Intermittent fasting significantly reduces body weight and BMI in overweight and obese adults compared to control diets, with alternate-day fasting showing superior weight loss effects compared to time-restricted eating.Good
- Intermittent fasting significantly improves lipid profiles by reducing total cholesterol and LDL, but may temporarily increase triglycerides in short-term interventions (≤ 12 weeks).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →